التفاصيل البيبلوغرافية
| العنوان: |
Targeted agents and combinations in ovarian cancer: where are we now? |
| المؤلفون: |
McLachlan, Jennifer, Lima, Joao Paulo da Silveira Nogueira, Dumas, Lucy, Banerjee, Susana |
| المصدر: |
Expert Review of Anticancer Therapy; Apr2016, Vol. 16 Issue 4, p441-454, 14p |
| مصطلحات موضوعية: |
NEOVASCULARIZATION inhibitors, FOLIC acid antagonists, ANTINEOPLASTIC agents, CELL receptors, DRUG therapy, OVARIAN tumors, TRANSFERASES, INDOLE compounds, PHARMACODYNAMICS, THERAPEUTICS |
| مستخلص: |
Epithelial ovarian cancer is a heterogeneous disease with distinct histological subtypes characterized by different patterns of clinical behaviour. The identification of molecular pathways associated with individual subtypes has fuelled enthusiasm for the development of targeted therapies directed at specific subtypes of ovarian cancer. To date, the most successful targeted therapies in ovarian cancer to have undergone clinical development include anti-angiogenic agents and PARP inhibitors. Other promising areas of development include folate receptor antagonists, MEK and BRAF inhibitors in low-grade serous carcinoma, and immunotherapy. These novel therapeutic agents have the potential to maximize tumor efficacy, minimize toxicity and improve outcomes for women with epithelial ovarian cancer. [ABSTRACT FROM PUBLISHER] |
|
Copyright of Expert Review of Anticancer Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
